Disease Info Card

Myositis Ossificans

Information about Myositis Ossificans: characteristics, related genes and pathways, plus antibodies you can use for research. This page is being enriched constantly, if you see some information you would like this page to include please send your suggestions to us.

Overview of Myositis Ossificans

Most recent studies have shown that Myositis Ossificans shares some biological mechanisms with athletic-injuries, bone-neoplasms, calcinosis, congenital-abnormality, edema, fibrodysplasia-ossificans-progressiva, fracture, hereditary-diseases, heterotopic-ossification, malignant-neoplasms, malignant-paraganglionic-neoplasm, myopathy, myositis, myositis-ossificans-circumscripta, neoplasms, osteosarcoma, pain, sarcoma, soft-tissue-neoplasms, traumatic-myositis-ossificans.

Among the many pathways, these few ones have gauged particular interests from scientists studying Myositis Ossificans, and have been seen in publications frequently: Angiogenesis, Bmp Signaling Pathway, Bone Remodeling, Cell Proliferation, Endochondral Ossification, Excretion, Localization, Mastication, Metaplastic Ossification, Muscle Atrophy, Muscle Hypertrophy, Ossification, Osteoblast Differentiation, Pathogenesis, Protein Phosphorylation, Regeneration, Rna Interference, Segmentation, Transport, Transposition

Quite a number of genes have been found to play important roles in Myositis Ossificans, such as ACVR1, BMP2, BMP4, CHTOP, CRAT, FGFR1OP, FKBP1A, GLYAT, HHIP, HNRNPC, NOG, POMC, REG3A, RPL29, SMAD1, ST13, VIM. See what Boster has to offer for the research of these genes by clicking the gene name links below and view a more detailed info card/product listing for that gene.

In a later update, we will include information such as current drugs and therapy solutions as well as on-going and past clinical trials for this disease. Plesae stay updated.